reports
- Oscar Haffen Lamm
BioInvent: Updated ph2a data on BI-1808 in CTCL shared at EHA
At EHA, BioInvent shared updated phase 2a data on BI-1808 in CTCL. Among 9 evaluable CTCL patients (7 SS, 2 MF), results showed 1 CR (SS), 3 PRs (2 SS, 1 MF), and 5 SDs - resulting in an ORR of c. 45% and a DCR of 100%. In PTCL, 2 patients were evaluable with 1 PR and 1 SD. On the safety front, all
- Oscar Haffen Lamm
BioInvent: BI-1206 & pembro combo enters phase 2a, targeting 1L NSCLC ...
BioInvent has completed the phase 1 portion of its trial evaluating BI-1206 in combination with pembrolizumab across solid tumors and will initiate the phase 2a expansion, targeting 1L NSCLC and 1L uveal melanoma (UM), with enrollment expected in H2 2025. Initial data readouts are anticipated in 20
- Oscar Haffen Lamm
Mgmt lunch takeaways: CTCL pivotal in sight, BI-1206 triplet poised to...
Yesterday, we attended a lunch organised by BioInvent's management, where the team provided updated colour on lead programs BI-1808 in CTCL and BI-1206 in NHL. An important strategic focus for the company is the advancement of BI-1808 in CTCL, where early signs of clinical activity in both Sézary S
- Oscar Haffen Lamm
BioInvent: BI-1808 meets bar in CTCL; BI-1206 in NHL slightly below th...
Yesterday afternoon, the company released new data from two programs: BI-1808 in CTCL and BI-1206 (triple combo with AZ's Calquence) in NHL. For BI-1808 in CTCL, the dataset now includes 8 patients (up from 4 previously), showing 1 new complete response (CR), 3 partial responses (PR), and 4 stable
- Oscar Haffen Lamm
BioInvent Q1: Making steady progress, key readouts ahead
BioInvent reported Q1'25 results which mainly focused on balance sheet items and a recap of corporate achievements for the quarter, with opex roughly in line with our estimates at SEK(144.8m) (runway mid-2026). Importantly, several key upcoming catalysts have been reiterated for mid-2025 on both le
- Oscar Haffen Lamm
BioInvent: Outlicensed program to Takeda moving into phase 3
During trading hours yesterday, BioInvent announced that following Takeda's initiation of the phase 3 clinical trial of mezagitamab (TAK-079) in ITP, an anti-CD38 licensed from BioInvent's R&D engine, the company received a USD1m milestone payment. Of note, Takeda is forecasting between USD1-3b
- Oscar Haffen Lamm
BioInvent: Initiating coverage on a rising force in immuno-oncology wi...
BioInvent is a Swedish immuno-oncology company backed by a strong R&D platform that has been validated over the years through multiple strategic partnerships with leading pharma companies. Two lead assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcyRIIB), are progressing through clinical trials,
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.